Trial Profile
A Remote, Double-Blind, Randomized, Placebo-Controlled Study of Rotigotine Transdermal System in Adolescent Subjects With Idiopathic Restless Legs Syndrome
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 28 Oct 2023
Price :
$35
*
At a glance
- Drugs Rotigotine (Primary)
- Indications Restless legs syndrome
- Focus Adverse reactions; Therapeutic Use
- Sponsors UCB Biopharma
- 06 May 2023 Primary end-points have been updated to add 2 new safety end-points, thus making "AR" also a trial focus.
- 06 May 2023 Status changed from recruiting to discontinued due to Sponsor decision; Not a safety decision.
- 23 Jun 2020 Planned End Date changed from 1 Sep 2022 to 1 Oct 2023.